Related Experiment Video
Updated: Jun 21, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist
L Rihakova1, C Quiniou, F F Hamdan
1Departments of Pediatrics and Pharmacology, Hôpital Ste Justine, Research Center, Montreal, QC, Canada.
Summary
Researchers discovered VRQ397, a novel noncompetitive antagonist for the vasopressin type 2 receptor (V2R). This potent molecule selectively inhibits V2R function, offering a new approach for hydroosmotic regulation and potential therapeutic applications.
Area of Science:
- Pharmacology
- Molecular Biology
- Endocrinology
Background:
- The vasopressin type 2 receptor (V2R) plays a crucial role in regulating hydroosmotic balance.
- Current V2R drugs are competitive ligands, mimicking arginine vasopressin (AVP).
- Noncompetitive antagonism of V2R has not been previously demonstrated.
Purpose of the Study:
- To discover and characterize a novel noncompetitive antagonist for the V2R.
- To investigate the functional selectivity and allosteric modulation properties of the identified antagonist.
- To evaluate the in vivo efficacy of the antagonist in regulating water balance.
Main Methods:
- Design and screening of peptides targeting juxtamembranous regions of V2R.
- Characterization of the lead peptide (VRQ397) using functional assays (e.g., DDAVP-induced vasorelaxation).
- Assessment of binding kinetics, receptor specificity, signaling pathway effects (cAMP, PGI2, beta-arrestin2), and in vivo aquaretic activity.
Main Results:
- Identification of VRQ397 as a potent (IC50 = 0.69 ± 0.25 nM) noncompetitive V2R antagonist.
- VRQ397 inhibited V2R-dependent physiological function without displacing AVP binding, modulating its dissociation rate.
- VRQ397 demonstrated functional selectivity, inhibiting PGI2 generation but not cAMP or beta-arrestin2 recruitment, and showed in vivo aquaretic efficacy.
Conclusions:
- Discovery of the first potent noncompetitive V2R antagonist, VRQ397.
- VRQ397 acts as a negative allosteric modulator with functional selectivity.
- This finding opens new avenues for V2R-targeted therapies with improved specificity.
Related Concept Videos
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...